Of taxes and tariffs; the dealing begins; yelling at Yellin; Paul Singer not amused by Bloomberg report; and more!

Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

In sub-Saharan Africa, high levels of particulate matter (PM2.5) pollution from vehicle tailpipe emissions cause poor health, ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...

Detailed price information for Avid Bioservices Inc (CDMO-Q) from The Globe and Mail including charting and trades.

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.